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Abstract
Background The technical advantages in utilizing human
acellular dermal matrix (ADM) products as pectoral extenders
in immediate breast reconstruction with tissue expanders or
implants are well documented in the medical literature. In this
study, the authors examine a commonly used biologic
xenograft product that has not yet been described in the
medical literature for use in immediate breast reconstruction to
determine whether a lower overall complication rate is
identified compared to published data on ADM products.
Methods A retrospective multicenter medical record review
of data on 54 subjects in 93 tissue expander/implant-based,
consecutive, immediate breast reconstructions from three
surgeons at different institutions was performed in which
Veritas® bovine pericardium was used as the biologic graft
material for the pectoral extender.
Results Over a 24-month period with an average of 11-month
follow-up, complication rates using Veritas® in breast
reconstruction for seroma formation (7.5 %), marginal
skin flap necrosis (5.4 %) infection (6.5 %), and capsular
contracture (0 %) were found to compare equally or favorably
with statistically significant lower overall complications
relative to one comparison study and lower rates of
marginal skin flap necrosis relative to two comparison studies
based upon previously published data from multisurgeon
studies using ADM products.
Conclusions Overall complications were found to be lower
with Veritas® than ADM products in comparable multisurgeon
studies, though this was found to be statistically significant in
only one comparison study.
Level of Evidence: Level II, theraputic study.
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Introduction
There has been nearly a decade of experience with
biologic graft material to assist with implant-based,
post-mastectomy breast reconstruction and revisionary
breast surgery [1]. The reported benefits of utilizing
grafts as pectoral extenders include the ability to add
greater tissue expander volume at the time of surgery and
decreased postsurgical tissue expansion, facilitated direct to
implant reconstruction, improved inframammary fold
definition and decreased rates of capsular contracture
[2–6]. To date, the vast majority of published reports
have chronicled the experience with allograft and xeno-
graft acellular dermal matrix (ADM) products for breast
reconstruction and for revisionary breast surgery. Abundant
outcomes data comparing complication rates utilizing ADM
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products and conventional submuscular placement of tissue
expanders is available [7–12].
Despite the reported technical benefits of using ADM
products for breast reconstruction, several large multisurgeon
studies comparing conventional tissue expander reconstruction
with those involving ADM grafts have documented increased
rates of seroma formation, mastectomy skin flap necrosis,
infection, and overall complications [8–10]. In an effort to
maintain the technical benefits of breast reconstruction using
biologic grafts as pectoral extenders, a commonly used, but not
yet studied, material for use in breast reconstruction, Veritas®
bovine pericardium (Synovis Surgical Innovations, St. Paul,
MN, USA), a non-ADM xenograft, was evaluated in tissue
expander and implant-based breast reconstruction. This study
was performed to determine whether noted advantages using
ADM products, such as ease of use, ease of setting the
inframammary fold, and low rates of capsular contracture could
be achieved with lower rates of seroma formation, infection,
marginal skin flap necrosis, and overall complications relative
to ADM products. An extensive history of use with noncross-
linked bovine pericardium for abdominal wall, urogynecologic,
neurosurgical, and cardiothoracic reconstruction has been well
established, suggesting that it may be an ideal biocompatible
material for reconstructive and revisionary breast surgery
[13–16].
Materials and methods
A multicenter, retrospective medical record review was
performed for consecutive Veritas® patients who underwent
mastectomy with immediate breast reconstruction between
2009 and 2010 at three different medical institutions by three
different surgeons (MMM, MSM, and MSL). The study
method and design were reviewed and approved by
the Western Institutional Review board and Health Partners
Institutional Review board. A total of 54 subjects yielding
data on 93 consecutive tissue expander/implant-based
immediate breast reconstructions were included over
the 24-month period. Patients meeting the inclusion criteria
were over the age of 18 and underwent mastectomy with
immediate breast reconstruction using Veritas® collagen
matrix. Patients who underwent delayed breast reconstruction,
reconstruction with a biologic graft other than Veritas®, or
patients with concurrent autologous flap reconstruction
were excluded from the study. Data on age, body mass
index, use of prophylactic antibiotics, mastectomy weight,
duration of surgical drainage, cancer stage, chemotherapy
and radiation history, presence of comorbidities, including
diabetes, hypertension, cardiac disease, and smoking history
were tabulated.
The duration of postsurgical expansion prior to implant
exchange and all complications including seroma formation,
hematoma, marginal skin flap necrosis, infection, capsular
contracture, and need for tissue expander or implant removal
resulting in failure of the reconstructive effort were analyzed.
Seromas were subdivided into minor seromas requiring only
office-based drainage and major seromas requiring operative
drain placement. Infections were also subdivided into major
infections requiring inpatient hospitalization and/or implant
removal and minor infections requiring outpatient oral
antibiotic treatment. Bilateral mastectomies were recorded as
two separate cases.
Prophylactic intravenous antibiotic use and intraoperative
antibiotic irrigation with bacitracin solution for tissue
expanders and implants was recorded for all patients. The
surgical technique utilized entailed submuscular dissection
of the pectoralis major muscle, suturing of the Veritas®
bovine pericardium to the inframammary fold, caudal edge
of the pectoralis muscle, and the serratus anterior muscle
laterally with 2–0 polydiaxone suture, thus enveloping the
tissue expander/implant with Veritas® for inferior pole
coverage. Tissue expanders were filled intraoperatively
to allow for minimal skin tension on mastectomy skin flaps
(Fig. 1). One or two drains above the pectoralis major muscle
and exiting the axilla were used on all patients.
For statistical analysis, a logistic regression was used to
perform univariate analyses on each patient demographic
and comorbidity to determine if a relationship exists with
the occurrence of any study complication. Any potential risk
factor that rendered a p<0.10 was retained for a subsequent
multivariate analysis. Patient demographics, comorbidities,
and all complication rates were compared with previously
published data of multisurgeon clinical studies using ADM
products and control studies with no biologic and total
submuscular tissue expander coverage.
Fig. 1 Intraoperative placement of a 6-×18-cm sheet of Veritas®
secured to the caudal edge of the pectoralis major muscle, inframam-
mary fold, and serratus anterior muscle over a tissue expander with 2–0
polydioxanone sutures.
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Results
Over a 24-month period, a total of 54 patients underwent 93
immediate breast reconstructive procedures with tissue
expanders or implants. Three plastic surgeons performed
reconstructive procedures at three different medical institutions
utilizing a standardized technique for breast reconstruction with
Veritas® bovine pericardium as a pectoral extender. There were
no significant differences in patient characteristics between
surgeons, including age, comorbidities, smoking status,
radiation and chemotherapy history, cancer stage, body
mass index, or mastectomy specimen weight. The mean
period of follow-up was 11 months. Pre- or postoperative
radiation therapy was recorded in 16.7 % of cases.
Chemotherapy was administered postoperatively in
27.8 % of subjects and preoperatively in 3.7 % of
subjects. In addition, 25.9 % of subjects were former
smokers, and 3.7 % were present smokers. Postsurgical
drains were placed for an average of 10.1 days. In
patients receiving tissue expanders, the average duration
to implant exchange was 20.6 weeks. Eighteen patients
(33.3 %) underwent single-stage reconstruction with silicone
implants in one or both breasts, 34 patients (63 %) of patients
underwent two-stage reconstruction with a tissue expander
and Veritas® at the first stage and a silicone implant at the
second stage, and 2 patients (3.7 %) underwent a single-stage
reconstruction in one breast and a two-stage reconstruction in
the other breast. This represented a total of 36 single stage
reconstructions (38.7 %) and 57 two-stage reconstructions
(61.3 %) (Table 1).
The seroma rate with Veritas® was 7.5 % with a 1.1 %
major seroma rate and a 6.4 % minor seroma rate. The
cumulative infection rate was 6.5 % with a 2.1 % major
infection rate and 4.3 % minor infection rate. Only two cases
of culture-specific microorganisms were identified in the study,
with one patient found to have Pseudomonas aeruginosa and
another patient a staphylococcal organism. Both of these
patients required implant removal. Marginal skin flap necrosis
was noted in 5.4 % of patients. There were no reported cases of
capsular contracture in the study over the 11-month follow-up
period. The presence of all complications was 21.5 % (Table 2,
Fig. 2). At least one complication was noted in 17 breasts
(18.3 %). There were no significant differences among
complication rates or demographics in the study between
tissue expander and single-stage implant reconstructions or
in complication rates between surgeons in the study.
Discussion
Many plastic surgeons have adopted the use of acellular
dermal matrix products in reconstructive and revisionary
breast surgery due to the technical advantages in setting
the inframammary fold, increased intraoperative fill volumes
of tissue expanders, the shorter duration of the expansion
process, facility in performing single-stage direct to implant
reconstructions, and the increasing body of evidence showing
lower documented capsular contracture rates [17]. The
enthusiasm for the use of ADMs has been tempered by
the higher reported rates of seroma formation, peri-prosthetic
infection, and mastectomy skin flap necrosis [8–10].
The ideal graft material for use in tissue expander/implant
breast reconstruction incorporates all of the advantages that
have been heretofore noted with ADM products but minimizes
complication rates and has a favorable relative cost of product
[18, 19]. In this study, the authors have determined that relative
to other multisurgeon published studies on ADM products in
breast reconstruction, Veritas® bovine pericardium exhibits a
lower overall complication rate of 21.5 %, though this was
found to be statistically significant only in comparison to one
other study byChun et al. (48.7%, p<0.0001) [8]. No statistical
significance of overall complication rates was found relative to
two other multisurgeon studies by Liu et al. and Antony et al.
[9, 10] Lower rates of infection and seroma were not found to
be statistically significant. A lower rate of marginal skin flap
necrosis (5.4%) was found to be statistically significant relative
to Chun et al. [8] (23.4 %, p<0.0001) and Liu et al. [10]
(13.9 %, p00.026). Veritas® was found to have a zero reported





Subjects per surgeon (%)
Site 1 15 (27.8 %)
Site 2 30 (55.6 %)
Site 3 9 (16.7 %)
Mean age, years ± SD 50.5±10.1
Mean BMI ± SD 24.6±4.7
Mean mastectomy specimen weight in grams ± SD 452.5±290.7
Diabetes (%) 2 (3.4 %)
Hypertension (%) 12 (22.2 %)
Carotid artery disease (%) 1 (1.9 %)
History of smoking (%)
Current smoker 2 (3.7 %)
Former smoker 14 (25.9 %)
Non smoker 38 (70.4 %)
Chemotherapy (%) 17 (31.5 %)
Radiation therapy (%) 9 (16.7 %)
Subjects with single-stage reconstruction (%) 18 (33.3 %)
Subjects with two-stage reconstruction (%) 34 (63.0 %)
Subjects with single-/two-stage reconstruction (%) 2 (3.7 %)
Breasts with single-stage reconstruction (%) 36 (38.7 %)
Breasts with two-stage reconstruction (%) 57 (61.3 %)
Mean duration of drain placement, days ± SD 10.1±6.0
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rate of capsular contracture over the follow up period in the
study.
Given the vast majority of seromas, infections and
mastectomy skin flap necrosis are identified within the
first several months after the performance of immediate
breast reconstruction after mastectomy, the relatively short
follow-up period of 11 months is believed to adequately
represent a true picture of the overall complication rate relative
to ADM products. With respect to capsular contracture,
though it represents a progressive phenomenon, Prantl et al.
found that 58 % of all contractures occurred within the first
11 months after implantation, 17 % within 3 years and 25 %
after 5 years [20]. It is possible that the clinical findings
associating low capsular contracture rates with ADM
products, which are thought to be related to the decrease in
inflammatorymediators, myofibroblasts, fibroblast cellularity,
and foreign body giant cell reaction, may also be applicable to
noncross-linked bovine pericardium.
Other innate properties of noncross-linked bovine
pericardium may also explain the favorable complication rate
Table 2 Comparison of com-
plication rates with Veritas® in
immediate breast reconstruction
with AlloDerm® (previously
published data) in multi-surgeon
studies
Complication Veritas® (n093) Chun et al. [8]
AlloDerm
(n0269)
Lui et al. [10]
AlloDerm
(n0266)
Antony et al. [9]
AlloDerm
(n0153)
p value p value p value
All complications by
breast (%)




17 (18.3 %) – – –
Seroma (%) 7 (7.5 %) 38 (14.1 %) 19 (7.1 %) 11 (7.2 %)
p00.104 p01.000 p01.000
Major 1 (1.1 %) – – –
Minor 6 (6.4 %) – – –
Marginal skin flap
necrosis (%)
5 (5.4 %) 63 (23.4 %) 37 (13.9 %) 7 (4.6 %)
p<0.0001 p00.026 p00.769
Infection (%) 6 (6.5 %) 24 (8.9 %) 18 (6.8 %) 11 (7.2 %)
(includes cellulitis)
p00.521 p01.000 p01.000
Major 2 (2.1 %) 22 (8.2 %) 13 (4.9 %) –
P00.052 P00.371
Minor 4 (4.3 %) 2 (0.7 %) 5 (1.9 %) –
p00.040 p00.245
Hematoma (%) 2 (2.2 %) 6 (2.2 %) 1 (0.4 %) 3 (2.0 %)
1.000 0.166 1.000
Capsular contracture 0 (0 %) – – –
Fig. 2 Bar graph of
complication rates with
Veritas® in immediate breast
reconstruction as compared to
AlloDerm® from previously
published data in multisurgeon
studies [8–10]
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noted in this study relative to one other multisurgeon,
multicenter clinical study. As a thinner product [21],
Veritas® has been found, in histological and biomechan-
ical abdominal wall studies, to have superior capacity
for host revascularization relative to ADM products. In
an incisional hernia study by Deeken et al. in the pig
model, at 1 year, no differences in strength or stiffness
of the repair site were noted between AlloDerm® and
Veritas®. At 1, 6, and 12 months, however, Veritas®
scored significantly higher than AlloDerm® in histological
analyses of remodeling with greater host cellular infiltration,
fewer inflammatory cells, higher levels of extracellular matrix
deposition, greater neovascularization, and markedly less
fibrous encapsulation [22]. It is also possible that the
lower rates of marginal skin flap necrosis noted by the
authors of this study may be related to a less zealous
approach to intraoperative expansion of the tissue
expanders relative to surgeons in other studies.
From a technical standpoint, the lower elastin content of
bovine pericardium (2.98 %) relative to ADM products
(5–7 %) [21] may be an advantage in maximizing the soft
tissue coverage afforded by the pectoralis major muscle and in
preventing the window shading of the caudal muscle edge
during the expansion process. Products with higher elastin
content such as AlloDerm® may be more prone to stretch,
exhibit less stiffness, and experience greater deformation in
response to force displacement [13].
As the cost of biologic graft materials is becoming
increasingly important, given the economic constraints of
the provision of reconstructive breast procedures and health
care in general, the cost per square centimeter of Veritas®
bovine pericardium compares favorably to AlloDerm®. A
6-×18-cm sheet of Veritas® has a list price of $3,024 or
$28.00/cm2. A 6-×16-cm “thick” AlloDerm® sheet has a
list price of $3,562 or $37.10 cm2 [23] This represents a 25 %
reduction in price relative to a similar sized sheet of AlloDerm®.
Despite these advantages identified with Veritas® bovine
pericardium for immediate breast reconstruction, properties
inherent to the thin nature of the material make it less
attractive for use than ADM products for the specific
purpose of camouflaging the rippling and wrinkling
noted in secondary breast reconstruction or in aesthetic
revisionary breast surgery. The increased thickness
afforded with thick or ultrathick ADM products provide
a higher degree of soft tissue augmentation over palpable or
visible implants, especially in the upper pole [24, 25]. The
greatest degree of soft tissue interposition in implant-based
breast reconstruction is afforded by the submuscular
placement of expanders and implants in the upper pole,
though, at times, additional augmentation of the soft
tissue envelope is possible with autologous fat grafting
or adjunctive placement of biologic graft material in
secondary procedures.
Conclusion
The authors present the first multicenter, multisurgeon,
retrospective study of Veritas® bovine pericardium for
use in immediate reconstruction as a biologic graft
pectoral extender after mastectomy using tissue expanders or
implants. Overall complications were found to be lower with
Veritas® than ADM products in comparable multisurgeon
studies though this was found to be statistically significant in
only one comparison study. A zero rate of capsular contracture
over 11 months following implantation is noted. A lower
overall cost of product is noted relative to AlloDerm®.
Additional studies are needed to confirm these findings
and to determine whether the extracellular mechanisms
responsible for seroma formation, infection, skin flap
necrosis, and capsular contracture are in fact relatively
modulated in response to the materials tested.
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